<?xml version="1.0" encoding="UTF-8"?>
<p>Hendra virus subunit vaccine, an approved veterinary vaccine for equines in Australia, and a monoclonal antibody vaccine (m102.4) targeting the NiV recombinant viral envelope protein have proven their efficacy in various animal models; the latter has been administered on compassionate grounds to critical NiV patients [
 <xref rid="B67-viruses-12-00465" ref-type="bibr">67</xref>]. Non-human primates (African green monkeys) challenged with NiV survived the infection on administration of the vaccine (m102.4) even after symptomatic conditions, providing hope for similar efforts looking towards successful medicine/vaccine development.
</p>
